格隆汇2月10日｜OpenAI：我们今天开始在美国向部分免费和Go计划订阅用户推出ChatGPT广告的测试。

Oracle, Palantir among market cap stock movers on Monday By Investing.com Investing.com Australia

Doximity connects U.S. medical professionals through a cloud-based digital platform serving healthcare and pharmaceutical clients. What happened According to a Securities and Exchange Commission (SEC) filing dated Feb. 9, 2026, William Blair Investment Management, LLC reduced its position in Doximity (DOCS 0.51%) by 372,184 shares during the fourth quarter of 2025. The estimated transaction value was $20.89 million, calculated using the average closing price over the quarter. The quarter-end value of the Doximity stake decreased by $184.77 million, reflecting both share sales and stock price movements. What else to know This sale was a partial reduction; Doximity represented 0.67% of the fund’s reportable assets under management at quarter-end. Top holdings after the filing: Nvidia : $1.98 billion (5.5% of AUM) Taiwan Semiconductor Manufacturing : $1.82 billion (5.1% of AUM) Microsoft : $1.69 billion (4.7% of AUM) Apple : $1.48 billion (4.1% of AUM) Amazon : $1.01 billion (2.8% of AUM) As of Feb. 6, 2026, Doximity shares were priced at $27.73, down 66% from a year earlier, underperforming the S&P 500 by 82 percentage points over that period. Company Overview Metric Value Price (as of market close 2/6/26) $27.73 Market Capitalization $5.09 billion Revenue (TTM) $637.78 million Net Income (TTM) $239.40 million Company Snapshot Doximity: Operates a cloud-based digital platform offering collaboration, telehealth, and career management tools for medical professionals in the United States. Generates revenue primarily from pharmaceutical manufacturers and healthcare systems. Targets physicians, healthcare providers, and medical organizations as its primary customer base. Doximity connects U.S. medical professionals through a cloud-based digital platform serving healthcare and pharmaceutical clients. Doximity is a leading healthcare information services provider that leverages a robust digital platform to connect and empower medical professionals. What this transaction mean...

Oracle, Palantir among market cap stock movers on Monday By Investing.com Investing.com South Africa

DNY59/iStock via Getty Images Summary As explained in Prof. Robert Jarrow’s book cited below, forward rates contain a risk premium above and beyond the market’s expectations for the 3-month forward rate. We document the size of that risk premium in this graph, which shows the zero-coupon yield curve implied by current Treasury prices compared with the annualized compounded yield on 3-month Treasury bills that market participants would expect based on the daily movement of government bond yields in 14 countries since 1962. The risk premium, the reward for a long-term investment, is large and widens over most of the full 30-year maturity range. The graph also shows a decline in expected yields at a steady pace for the full 30 years. We explain the details below. SAS Institute Inc. For more on this topic, see the analysis of government bond yields in 14 countries through November 30, 2025 given in the appendix. Inverted Yields, Negative Rates, and U.S. Treasury Probabilities 10 Years Forward The negative 2-year/10-year Treasury spread ended on August 26, 2024 after 537 trading days. The spread is currently at positive 0.72%. The table below shows that the August 26, 2024 streak of inverted yield curves is the longest in the U.S. Treasury market since the 2-year Treasury yield was first reported on June 1, 1976. The second longest streak is 423 trading days starting on August 18, 1978. SAS Institute Inc. In this week’s forecast, the focus is on three elements of interest rate behavior: the future probability of the recession-predicting inverted yield curve, the probability of negative rates, and the probability distribution of U.S. Treasury yields over the next decade. We start from the closing U.S. Treasury yield curve published daily by the U.S. Department of the Treasury. Using a maximum smoothness forward rate approach, Friday’s implied forward rate curve shows the shortest maturity 1-month forward rates at 3.72%, versus 3.72% last week. There is a decline followed ...

Key Points Vertex's core franchise probably won't lead to any surprises, but newer launches could. The company should see significant pipeline progress this year. Vertex looks like a strong buy-and-hold option. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ: VRTX) experienced several setbacks last year, sometimes following quarterly updates that weren't as strong as the market expected, or during which it also reported clinical trial failures. The company's shares are slightly in the red over the trailing-12-month period, partly due to these issues. The biotech is set to release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 12. Will the stock dip again after its earnings, or should investors consider buying Vertex's shares ahead of its upcoming quarterly update? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » What should investors expect? Vertex Pharmaceuticals remains the leader -- and the only player for that matter -- in the market for medicines for cystic fibrosis (CF). In its upcoming quarterly update, we should once again see that its CF drug portfolio drove decent top-line growth. Vertex Pharmaceuticals projected revenue of $11.9 billion to $12 billion for fiscal year 2025, implying year-over-year growth of at least 8%. Could we see Vertex Pharmaceuticals landing toward the upper end of its guidance range, perhaps even beating it? If it does, it might be because of progress with other approved products, namely Casgevy, which treats two blood-related disorders, and Journavx for acute pain. Vertex Pharmaceuticals noted that more than 170 million U.S. patients already have third-party coverage for Journavx, which was approved last year. Casgevy's uptake has been slower, as it is a gene-editing medicine, which is complex to admi...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Earnings Call Insights: Jerash Holdings (JRSH) Q3 2026 Management View CEO Lin Choi reported, "Jerash achieved sharply improved financial results across both top line and bottom lines for the fiscal third quarter. The performance reflected continued growing demand from our long-standing global customers complemented by initial large orders placed in June from our new strategic partner, Hansoll Textile in Korea." Choi highlighted the acquisition of a 184,000 square foot manufacturing building and land in Amman, Jordan, calling it "an important milestone as we advance the company's next 5-year growth strategy." He stated, "Once fully operational, this strategic investment is expected to increase our manufacturing capacity for -- by at least 40%." Eric Tang, Head of Operations of Jordan, stated, "We are now completing production of the final phase of the initial order of 3 million pieces of girls' short from Hansoll with shipments expected to be completed during the current fiscal quarter." Tang indicated that the company is working on a second purchase order for a different style and that "our facilities are now fully booked through July with customers' commitments coming in for the rest of the calendar year soon." CFO Gilbert Kwong-Yiu Lee reported, "Revenue for the fiscal 2026 third quarter grew 18% to $41.8 million from $35.4 million in the same quarter last year." Lee added, "Operating income nearly tripled to $1.9 million in the fiscal 2026 third quarter from $708,000 in the same quarter last year." Outlook The company expects revenue for the fiscal 2026 fourth quarter to increase by 23% to 26% over the same quarter last year, while targeting a gross margin of 14% to 16%. Management noted, "We want to note that the Ramadan holiday this year falls at the end of March, whereas last year, it occurred in early April. Depending on production and shipping schedules, some shipments may experience delay into the following quarter." Financial Results CFO Lee stated, "Gros...

Oracle, Palantir among market cap stock movers on Monday Investing.com

格隆汇2月10日｜市场消息：AMD(AMD.O)任命阿里尔·凯尔曼为首席营销官，凯尔曼曾任Salesforce总裁兼首席营销官。

Why is Google-Alphabet’s GOOG stock surging along with the VIX today? Cryptopolitan

Tech Giants Scramble as New Chip Innovations Threaten Market Equilibrium StocksToTrade

Oracle, Palantir among market cap stock movers on Monday By Investing.com Investing.com Canada

美財政部官員訪華 籌備下輪美中經貿會談 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】美國財政部高層官員上周訪華，籌備下一輪美中經貿磋商。 財長貝森特發文指，財政部高層官員訪華期間，跟中方官員磋商準備他和副總理何立峰再次會面。貝森特稱，雙方官員會面有助鞏固溝通渠道，推進兩國對話，美國期待跟中國維持建設性接觸，並於會面前的數周保持積極動力。

The technology company's recent results may or may not be what the market was led to believe. It's a rough start to the trading week for Kyndryl (KD 55.98%) investors. As of 2:03 p.m. ET Monday, shares of the technology services outfit are down 54.5% following the release of its disappointing fiscal third-quarter results. It's not its Q3 numbers, however, that are responsible for most of today's sizable setback. Bad news, and worse news Kyndryl turned $3.9 billion worth of revenue into net income of $57 million during the three months ending in December, or an adjusted profit of $0.52 per share. While sales and earnings were up slightly year-over-year, both also fell short of expectations. Worse, the company lowered its revenue guidance for the current fiscal year. It's now anticipating free cash flow of between $325 million and $375 million on revenue that will be between 2% and 3% lower than last year's, versus an expectation for free cash flow of around $550 million just three months earlier, when Kyndryl was looking for a slight uptick in its full-year top line. Expand NYSE : KD Kyndryl Today's Change ( -55.98 %) $ -13.15 Current Price $ 10.34 Key Data Points Market Cap $5.4B Day's Range $ 10.11 - $ 11.42 52wk Range $ 10.11 - $ 44.20 Volume 1M Avg Vol 2.3M Gross Margin 21.50 % That's still not the crux of today's steep sell-off, though. Far more alarming to shareholders is the unexpected exit of now-former CFO David Wyshner and the simultaneous disclosure that the company's quarterly 10-Q filing with the Securities and Exchange Commission would be delayed because Kyndryl "is reviewing its cash management practices, related disclosures (including regarding the drivers of the Company's adjusted free cash flow metric), the efficacy of the Company's internal control over financial reporting." Ultimately, "the Company anticipates reporting material weaknesses in the Company's internal control over financial reporting for the period covered in the Quarterly Report, as...

格隆汇2月10日｜当地时间9日，以军当天继续对约旦河西岸多地开展突袭和拆毁行动，造成多人受伤，以军还强行拘留了20多名巴勒斯坦人，其中包括妇女和儿童。同一天，以军发布公告，证实9日凌晨以色列国防军与以色列安全局在约旦河西岸多地开展联合行动，行动中逮捕20余名武装人员。

Bitcoin’s price fell below $70,000 on Monday, a slump from a peak of $126,000 last October, as investors grapple with existential questions about what crypto is for. Jalak Jobanputra, founder and managing partner of Future\Perfect Ventures, discusses opportunities in the sector with Caroline Hyde and Ed Ludlow on “Bloomberg Tech.” (Source: Bloomberg)

March NY world sugar #11 (SBH25) Tuesday closed down -0.03 (-0.14%), and December London ICE white sugar #5 (SWZ24) closed up +0.40 (+0.07%). Sugar prices on Tuesday settled mixed. Sugar has been under pressure recently, with NY sugar posting a 2-week low Monday and London sugar posting a 1-1/2 month low Tuesday on forecasts for beneficial rain in Brazil's Center-South that eases concerns over excessive dryness. Forecaster Climatempo said rain will continue in Brazil's Center-South region over the next few days. Brazil's Center-South is the country's main sugar-producing region. However, sugar prices recouped most of their losses Tuesday, with London sugar pushing into positive territory as short covering emerged in sugar futures when the dollar index (DXY00) fell to a 2-1/2 week low. An excessive long position by funds in London sugar may fuel long liquidation and exacerbate any price downturn. Last Friday's weekly Commitment of Traders (COT) report showed funds boosted their net-long London sugar positions by 453 in the week to October 29 to 42,804 net-long positions, the most since data began in 2011. A bearish factor for sugar was the report from Unica on October 25 that showed sugar output in Brazil's Center-South region during the first half of October rose +8% y/y to 2.443 MMT. Also, cumulative 2024/25 Center-South sugar output through the first half of October rose +1.9% to 35.591 MMT. Sugar prices are also undercut after India's Sugar Mills asked the government on Tuesday to permit them to export 2 million MT of sugar immediately due to the nation's surplus. Recent drought and excessive heat caused fires in Brazil that damaged sugar crops in Brazil's top sugar-producing state of Sao Paulo. Sugar cane industry group Orplana said that as many as 2,000 fire outbreaks affected up to 80,000 hectares of planted sugarcane in Sao Paulo. Green Pool Commodity Specialists said that as much as 5 MMT of sugar cane may have been lost due to the fires. Conab, Brazil's gov...

Oracle, Palantir among market cap stock movers on Monday By Investing.com Investing.com UK

在岸人民币兑美元（CNY）北京时间03:00收报6.9208元，较上周五夜盘收盘涨146点。成交量441.84亿美元。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

格隆汇2月10日｜据Punchbowl：Anthropic首席执行官将于周二与参议院银行委员会的共和党参议员会面。

格隆汇2月10日｜恒指期货夜盘收涨0.62%，报27221点，高水194点。

Financial stocks were mixed in Monday afternoon trading, with the NYSE Financial Index fractionally Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles.

This article first appeared on GuruFocus. Exploring Ken Fisher (Trades, Portfolio)'s Latest 13F Filing and Investment Strategy Ken Fisher (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insights into his investment moves during this period. Ken Fisher (Trades, Portfolio) is the Chief Executive Officer and Chief Investment Officer of Fisher Investments. He has been writing Forbes' prestigious "Portfolio Strategy" column for over two decades, making him one of the longest-running columnists in the magazine's 85+ year history. During his many years of money management and market commentary, Ken has distinguished himself by making numerous, accurate market calls, often in direct opposition to Wall Street's consensus forecast. He is the son of legendary investor Philip A. Fisher, and Ken is the only industry professional his father ever trained. Ken has also written three major finance books, including the 1984 Dow Jones best-seller, Super Stocks, and has been published and/or interviewed in many major global finance and business periodicals. The investment philosophy at Fisher Investments is based on the idea that supply and demand of securities is the sole determinant of their pricing. Furthermore, they believe that all widely known information has already been priced into the market. The way to add value, according to the Fisher strategy, is to "identify information not widely known, or to interpret widely known information differently and correctly from other market participants." Fisher Investments employs a team of research analysts to accomplish these tasks. Ken Fisher's Strategic Moves: iShares 7-10 Year Treasury Bond ETF Takes Center Stage Summary of New Buy Ken Fisher (Trades, Portfolio) added a total of 113 stocks, among them: The most significant addition was TotalEnergies SE (NYSE:TTE), with 19,324,336 shares, accounting for 0.43% of the portfolio and a total value of $1.26 billion. The second largest addition ...

Why Did Micron Stock Drop on Monday? aol.com

Shivering and rain-drenched at the side of a pond in Cornwall, a huddle of people watched in hushed silence as a beaver took its first tentative steps into its new habitat. As it dived into the water with a determined “plop” and began swimming laps, the suspense broke and everyone looked around, grinning. The soggy but momentous occasion marks the first time in English history that beavers have been legally released into a river system, almost one year after the government finally agreed to grant licences for releases. “It’s a beaver blind date,” said Cheryl Marriott, the director of nature and people for the Cornwall Wildlife Trust, as another made its way into the water. The two beavers released into a top-secret location at the Helman Tor reserve are from enclosures across the country: one from Cheshire and the other from Dorset. They were meeting for the first time on Monday when they were released together into the same pond, while two others were released at a nearby site. The beaver experts at the charity will be watching the pair closely to see if they get along. “The beaver trust has a stud book to ensure genetic diversity,” Marriott said. “We want these two to start a family. Beavers don’t tend to be too fussy about their partners, from what I understand, but sometimes they don’t hit it off. We hope this is the start of a self-sustaining population.” View image in fullscreen One of the beavers takes to the water. Photograph: Jim Wileman/The Guardian The first legal release under a new government licensing system happened last year on the National Trust’s Purbeck Heaths estate in Dorset. However, those beavers are contained on the local peninsula and cannot make their way up a river system. This is the first truly wild beaver release on the English mainland. Four hundred years ago, beavers were hunted to extinction in the UK, sought for their thick pelt and an oil they produce. But beavers are known as a keystone species that can rapidly improve the environ...

Pakistan are poised to fulfil their T20 World Cup fixture against India on Sunday, having previously been instructed by their government to boycott the game in a move that could have cost the sport millions. The crisis was triggered by Bangladesh withdrawing from the tournament last month – their place handed to Scotland – when a request to play their matches outside India on security grounds was rejected by the International Cricket Council. In an act of solidarity the Pakistan government, led by the prime minister, Shehbaz Sharif, then stated Pakistan would forfeit the game against India in Colombo – a potentially damaging move given the fixture’s centrality to the ICC’s £2.2bn ($3bn) broadcast deal. But after talks between the ICC, the Pakistan Cricket Board and the Bangladesh Cricket Board in Lahore in the past few days – plus representations from the co-hosts, Sri Lanka – the impasse has been broken. As part of the deal, Bangladesh will face no censure for the withdrawal and have been handed hosting rights for a future ICC tournament, while Pakistan will drop their intended boycott of the India match. The Pakistan government on Monday evening said: “This decision has been taken with the aim of protecting the spirit of cricket, and to support the continuity of this global sport in all participating nations.” The ICC said: “It was agreed that all members will respect their commitments as per the terms of participation for ICC events and do all that is necessary to ensure that the ongoing edition of the ICC men’s T20 World Cup is a success.” Aminul Islam, the president of the BCB, had earlier requested the match between India and Pakistan go ahead “for the benefit of the entire cricket ecosystem”. He said: “We are deeply moved by Pakistan’s efforts to go above and beyond in supporting Bangladesh during this period. Long may our brotherhood flourish.”

Lock Stock/DigitalVision via Getty Images Over the weekend, Hims & Hers Health ( HIMS ) announced that it will no longer offer a compounded version of oral semaglutide, the active ingredient in Novo Nordisk's ( NVO ) weight loss pill Wegovy. In the short term, this headline is bullish for Novo and bearish for Hims, so traders may wish to position accordingly. However, this does not change my position that Novo faces a difficult outlook due to margin compression in the coming year. For Hims, selling has been brutal, with shares now trading below $17/share. I became interested in taking a closer look, particularly because Hims' GLP-1 business was projected to reach $725M in FY 2025 sales. With total FY 2025 sales estimates around $2.35B, ~70% of the business has nothing to do with weight loss. While the headline, legal and execution risks are real, Hims presents shareholders with value even in the base case that the GLP-1 business will significantly shrink or disappear. A close look at the balance sheet shows that Hims has cash to navigate this pivot. Ingenious fashion, Hims issued nearly $1B in convertible senior notes at 0% interest that will now almost certainly be repaid without diluting shareholders. Striping away intangible assets, Hims has a 'war chest' of $1.07B in cash, short-term investments and long-term investments, ensuring the company will continue as a going concern toward a future less dependent on GLP-1. However, that does not mean that today is the right time to buy. In light of the likelihood that Hims will need to stop offering compounded semaglutide, analysts' estimates for 17.5% YoY revenue growth in 2026 seem unlikely. These estimates will likely need to be revised lower, putting additional selling pressure on the stock. While long-term investors may be attracted to Hims for its post-GLP-1 future, lower prices seem inevitable first. Below, I will discuss when this 'washout' should abate, rating Hims & Hers Health a Hold at the present time. Hims...

联合国秘书长古特雷斯当地时间2月9日通过发言人发表声明表示，对以色列安全内阁决定在被占领的约旦河西岸A区和B区实施一系列所谓行政和执法措施深表关切。他警告说，包括该决定在内的当前局势发展正侵蚀“两国方案”的前景。声明重申，以色列在被占领西岸（包括东耶路撒冷）的所有定居点及其相关制度和基础设施均不具法律效力，公然违反国际法，包括联合国相关决议。声明指出，这类行动——包括以色列持续存在于被占领的巴勒斯坦领土——不仅具有破坏稳定的影响，而且正如国际法院所重申的那样，属于非法行为。 (央视新闻)

AMD Hires Ariel Kelman as Chief Marketing Officer marketscreener.com